Guía de Práctica Clínica para el abordaje de las complicaciones hipertensivas asociadas al embarazo

Giancarlo Buitrago-Gutiérrez, Alejandro Castro-Sanguino, Rodrigo Cifuentes-Borrero, Martha Patricia Ospino-Guzmán, Ingrid Arévalo-Rodríguez, Pío Iván Gómez-Sánchez, Representantes Grupo Desarrollador de la Guía - Universidad Nacional de Colombia - Alianza CINETS

Resumen


Objetivo: realizar recomendaciones para la atención de las complicaciones hipertensivas en el embarazo como parte integral de la “Guía de Práctica Clínica (GPC) para la prevención, detección temprana y tratamiento de las complicaciones del embarazo en Colombia”.

Materiales y métodos: el grupo desarrollador de la Guía (GDG) elaboró esta GPC durante 2011-2012 acorde con la Guía Metodológica para la elaboración de Guías de Atención Integral en el Sistema General de Seguridad Social en Salud colombiano, basándose en la evidencia científica disponible y sumando la participación activa de grupos de pacientes, sociedades científicas y grupos de interés. En particular, la evidencia de esta sección fue adaptada de la GPC “Hypertension in pregnancy: the management of hypertensive disorders during pregnancy” (National Institute of Care and Health Excellence - NICE - 2010) y actualizada por medio de procedimientos sistemáticos, tanto para la búsqueda y valoración de la evidencia como para la generación de recomendaciones. El nivel de evidencia y la fuerza de las recomendaciones fueron expresados por medio del sistema del Scottish Intercollegiate Guidelines Network (SIGN).

Resultados: se presentan las recomendaciones para la atención de las complicaciones hipertensivas en el embarazo. Estas incluyen cambios en la conducta del personal de salud y las instituciones para aumentar la probabilidad de obtener un resultado materno-fetal exitoso en las gestaciones con estas condiciones.

Conclusiones: se presenta una versión resumida de las recomendaciones y evidencia para la atención de las complicaciones hipertensivas en el embarazo, la cual se espera sea adoptada por los profesionales de salud encargados de la atención del embarazo en el país para disminuir la morbilidad y mortalidad asociada a la gestación.


Palabras clave


hipertensión; hipertensión inducida por el embarazo; guías de práctica clínica; práctica clínica basada en la evidencia; Colombia

Texto completo:

PDF

Referencias


Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988;158:892-8. Epub 1988/04/01.

National Collaborating Centre for Women's and Children's Health. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: NICE; 2010.

Brown MA, Lindheimer MD, de Swiet M, van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:IX-XIV. Epub 2002/06/05.

National Collaborating Centre for Women's and Children's Health-National Institute for Health and Clinical Excellence. Hypertension in pregnancy. London: Royal College of Obstetricians and Gynaecologists; 2010 (cited 2011 Sept 1). Disponible en: http://www.nice.org.uk/cg107.

Ministerio de Salud y Protección Social, Colciencias. Guía de práctica clínica para la prevención, detección temprana y tratamiento de las complicaciones del embarazo, parto o puerperio. Versión completa. Bogotá, Colombia: Alianza cinets; 2013. Disponible en: http://www.guiascolcienciasminproteccionsocialalianzacinets.org/index.php?option=com_wrapper&view=wrappe r&Itemid=552.

Ministerio de Salud y Protección Social, Colciencias. Guía de práctica clínica para la prevención, detección temprana y tratamiento de las complicaciones del embarazo, parto o puerperio. Versión para pacientes. Bogotá, Colombia: Alianza cinets; 2013. Disponible en: http://www.guiascolcienciasminproteccionsocialalianzacinets.org/index. php?option=com_wrapper&view=wrapper&Item id=552.

Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565. Epub 2005/03/04.

Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ. 2005;330:576-80. Epub 2005/03/12.

Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess. 2008;12:iii-iv, 1-270. Epub 2008/03/12.

Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2008;198:7-22. Epub 2008/01/02.

Siqueira FM, Cota LO, Costa JE, Haddad JP, Lana AM, Costa FO. Maternal periodontitis as a potential risk variable for preeclampsia: a case-control study. J Periodontol. 2008;79:207-15. Epub 2008/02/07.

Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007(2):CD004659. Epub 2007/04/20.

Meher S, Duley L. Nitric oxide for preventing preeclampsia and its complications. Cochrane Database Syst Rev. 2007(2):CD006490. Epub 2007/04/20.

Meher S, Duley L. Progesterone for preventing preeclampsia and its complications. Cochrane Database Syst Rev. 2006(4):CD006175. Epub 2006/10/21.

Churchill D, Beevers GD, Meher S, Rhodes C. Diuretics for preventing pre-eclampsia. Cochrane Database Syst Rev. 2007(1):CD004451. Epub 2007/01/27.

Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensinconverting enzyme DD women. Hypertension. 2005;45:86-91. Epub 2004/11/24.

Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2006(3):CD001059. Epub 2006/07/21.

Rumbold A, Duley L, Crowther CA, Haslam RR. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev. 2008(1):CD004227. Epub 2008/02/07.

Wen SW, Chen XK, Rodger M, White RR, Yang Q, Smith GN, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol. 2008;198:45 e1-7. Epub 2008/01/02.

Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev. 2006(3):CD003402. Epub 2006/07/21.

Meher S, Duley L. Garlic for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2006(3):CD006065. Epub 2006/07/21.

Meher S, Duley L. Rest during pregnancy for preventing pre-eclampsia and its complications in women with normal blood pressure. Cochrane Database Syst Rev. 2006(2):CD005939. Epub 2006/04/21.

Meher S, Duley L. Exercise or other physical activity for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2006(2):CD005942. Epub 2006/04/21.

Bonzini M, Coggon D, Palmer KT. Risk of prematurity, low birthweight and pre-eclampsia in relation to working hours and physical activities: a systematic review. Occup Environ Med. 2007;64:228-43. Epub 2006/11/11.

Antartani R, Ashok K. Effect of lycopene in prevention of preeclampsia in high risk pregnant women. Journal of the Turkish German Gynecology Association. 2011;12:35-8.

Banerjee S, Jeyaseelan S, Guleria R. Trial of lycopene to prevent pre-eclampsia in healthy primigravidas: results show some adverse effects. J Obstet Gynaecol Res. 2009;35:477-82. Epub 2009/06/17.

Basaran A, Basaran M, Topatan B. Combined vitamin C and E supplementation for the prevention of preeclampsia: a systematic review and meta-analysis. Obstet Gynecol Surv. 2010;65:653-67. Epub 2010/12/25.

Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguere Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2009;31:818-26. Epub 2009/11/28.

Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2009;116:402-14. Epub 2010/07/29.

Catov JM, Nohr EA, Bodnar LM, Knudson VK, Olsen SF, Olsen J. Association of periconceptional multivitamin use with reduced risk of preeclampsia among normal-weight women in the Danish National Birth Cohort. Am J Epidemiol. 2009;169:1304-11. Epub 2009/04/18.

Conde-Agudelo A, Romero R, Kusanovic JP, Hassan SS. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;204:503 e1-12. Epub 2011/05/03.

Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2010(8):CD001059. Epub 2010/08/06.

Imdad A, Jabeen A, Bhutta ZA. Role of calcium supplementation during pregnancy in reducing risk of developing gestational hypertensive disorders: a meta-analysis of studies from developing countries. BMC Public Health. 2011;11 Suppl 3:S18. Epub 2011/04/29.

Haugen M, Brantsaeter AL, Trogstad L, Alexander J, Roth C, Magnus P, et al. Vitamin D supplementation and reduced risk of preeclampsia in nulliparous women. Epidemiology. 2009;20:720-6. Epub 2009/05/20.

Lambers MJ, Groeneveld E, Hoozemans DA, Schats R, Homburg R, Lambalk CB, et al. Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. Hum Reprod. 2009;24:2447-50. Epub 2009/07/18.

Lin JH, Yang YK, Liu H, Lin QD, Zhang WY. Effect of antioxidants on amelioration of high-risk factors inducing hypertensive disorders in pregnancy. Chin Med J (Engl). 2011;123:2548-54. Epub 2010/11/03.

Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med. 2010;362:1282-91. Epub 2010/04/09.

Teran E, Hernandez I, Nieto B, Tavara R, Ocampo JE, Calle A. Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia. Int J Gynaecol Obstet. 2009;105:43-5. Epub 2009/01/22.

Waugh JJ, Clark TJ, Divakaran TG, Khan KS, Kilby MD. Accuracy of urinalysis dipstick techniques in predicting significant proteinuria in pregnancy. Obstet Gynecol. 2004;103:769-77. Epub 2004/03/31.

Gangaram R, Ojwang PJ, Moodley J, Maharaj D. The accuracy of urine dipsticks as a screening test for proteinuria in hypertensive disorders of pregnancy. Hypertens Pregnancy. 2005;24:117-23. Epub 2005/07/23.

Saikul S, Wiriyasirivaj B, Charoenchinont P. First 4-hour urinary protein - creatinine ratio for diagnosis of significant proteinuria in preeclampsia. J Med Assoc Thai. 2006;89 Suppl 4:S42-6. Epub 2007/08/30.

Rinehart BK, Terrone DA, Larmon JE, Perry KG, Jr., Martin RW, Martin JN, Jr. A 12-hour urine collection accurately assesses proteinuria in the hospitalized hypertensive gravida. J Perinatol. 1999;19:556-8. Epub 2000/01/25.

Waugh JJ, Bell SC, Kilby MD, Blackwell CN, Seed P, Shennan AH, et al. Optimal bedside urinalysis for the detection of proteinuria in hypertensive pregnancy: a study of diagnostic accuracy. BJOG. 2005;112:412-7. Epub 2005/03/22.

Al RA, Baykal C, Karacay O, Geyik PO, Altun S, Dolen I. Random urine protein-creatinine ratio to predict proteinuria in new-onset mild hypertension in late pregnancy. Obstet Gynecol. 2004;104:367-71. Epub 2004/08/05.

Dwyer BK, Gorman M, Carroll IR, Druzin M. Urinalysis vs urine protein-creatinine ratio to predict significant proteinuria in pregnancy. J Perinatol. 2008;28:461-7. Epub 2008/02/22.

Leanos-Miranda A, Marquez-Acosta J, Romero-Arauz F, Cardenas-Mondragon GM, Rivera-Leanos R, Isordia-Salas I, et al. Protein:creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy. Clin Chem. 2007;53:1623-8. Epub 2007/07/31.

Ramos JG, Martins-Costa SH, Mathias MM, Guerin YL, Barros EG. Urinary protein/creatinine ratio in hypertensive pregnant women. Hypertens Pregnancy. 1999;18:209-18. Epub 1999/12/10.

Wheeler TL, 2nd, Blackhurst DW, Dellinger EH, Ramsey PS. Usage of spot urine protein to creatinine ratios in the evaluation of preeclampsia. Am J Obstet Gynecol. 2007;196:465 e1-4. Epub 2007/05/01.

Sibai BM, Koch MA, Freire S, Pinto e Silva JL, Rudge MV, Martins-Costa S, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol. 2008;199:268 e1-9. Epub 2008/09/06.

Jacobs M, Nassar N, Roberts CL, Hadfield R, Morris JM, Ashton AW. Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol. 2011;9:77. Epub 2011/06/09.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005. Epub 2006/09/08.

Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, et al. Urinary placental growth factor and risk of preeclampsia. JAMA. 2005;293:77-85. Epub 2005/01/06.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-83. Epub 2004/02/07.

Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, et al. The interrelationship of complement-activation fragments and angiogenesisrelated factors in early pregnancy and their association with pre-eclampsia. BJOG. 2010;117:456-62. Epub 2010/01/16.

Westergaard HB, Langhoff-Roos J, Lingman G, Marsal K, Kreiner S. A critical appraisal of the use of umbilical artery Doppler ultrasound in high-risk pregnancies: use of meta-analyses in evidence-based obstetrics. Ultrasound Obstet Gynecol. 2001;17:466-76. Epub 2001/06/26.

Williams KP, Farquharson DF, Bebbington M, Dansereau J, Galerneau F, Wilson RD, et al. Screening for fetal well-being in a high-risk pregnant population comparing the nonstress test with umbilical artery Doppler velocimetry: a randomized controlled clinical trial. Am J Obstet Gynecol. 2003;188:1366-71. Epub 2003/05/16.

Frusca T, Soregaroli M, Platto C, Enterri L, Lojacono A, Valcamonico A. Uterine artery velocimetry in patients with gestational hypertension. Obstet Gynecol. 2003;102:136-40. Epub 2003/07/10.

Ferrier C, North RA, Becker G, Cincotta R, Fairley K, Kincaid-Smith P. Uterine artery waveform as a predictor of pregnancy outcome in women with underlying renal disease. Clin Nephrol. 1994;42:362-8. Epub 1994/12/01.

Parretti E, Mealli F, Magrini A, Cioni R, Mecacci F, La Torre P, et al. Cross-sectional and longitudinal evaluation of uterine artery Doppler velocimetry for the prediction of pre-eclampsia in normotensive women with specific risk factors. Ultrasound Obstet Gynecol. 2003;22:160-5. Epub 2003/08/09.

Coleman MA, McCowan LM, North RA. Midtrimester uterine artery Doppler screening as a predictor of adverse pregnancy outcome in high-risk women. Ultrasound Obstet Gynecol. 2000;15:7-12. Epub 2000/04/25.

Caforio L, Testa AC, Mastromarino C, Carducci B, Ciampelli M, Mansueto D, et al. Predictive value of uterine artery velocimetry at midgestation in low- and high-risk populations: a new perspective. Fetal Diagn Ther. 1999;14:201-5. Epub 1999/07/27.

Asnafi N, Hajian K. Mid-trimester uterine artery Doppler ultrasound as a predictor of adverse obstetric outcome in high-risk pregnancy. Taiwan J Obstet Gynecol. 2011;50:29-32. Epub 2011/04/13.

Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Schielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for firsttrimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv. 2011;66:225-39. Epub 2011/07/16.

Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in normal pregnancy. Cochrane Database Syst Rev. 2010(8):CD001450. Epub 2010/08/06.

Thangaratinam S, Coomarasamy A, O'Mahony F, Sharp S, Zamora J, Khan KS, et al. Estimation of proteinuria as a predictor of complications of preeclampsia: a systematic review. BMC Med. 2009;7:10. Epub 2009/03/26.

Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG. 2006;113:369-78. Epub 2006/03/24.

Nisell H, Palm K, Wolff K. Prediction of maternal and fetal complications in preeclampsia. Acta Obstet Gynecol Scand. 2000;79:19-23. Epub 2000/01/26.

Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy. 2007;26:447-62. Epub 2007/12/11.

Thangaratinam S, Koopmans CM, Iyengar S, Zamora J, Ismail KM, Mol BW, et al. Accuracy of liver function tests for predicting adverse maternal and fetal outcomes in women with preeclampsia: a systematic review. Acta Obstet Gynecol Scand. 2011;90:574-85. Epub 2011/03/02.

Elhassan EM, Mirghani OA, Habour AB, Adam I. Methyldopa versus no drug treatment in the management of mild pre-eclampsia. East Afr Med J. 2002;79:172-5. Epub 2003/03/11.

Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam S. Randomised controlled trial of methyldopa and isradipine in preeclampsia-effects on uteroplacental and fetal hemodynamics. J Perinat Med. 1996;24:177-84. Epub 1996/01/01.

Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol. 1987;70:323-7. Epub 1987/09/01.

Sibai BM, Barton JR, Akl S, Sarinoglu C, Mercer BM. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol. 1992;167:879-84. Epub 1992/10/01.

Jabeen M, Yakoob MY, Imdad A, Bhutta ZA. Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths. BMC Public Health. 2011;11 Suppl 3:S6. Epub 2011/04/29.

Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010(11):CD000025. Epub 2010/11/12.

Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium sulphate regimens for women with preeclampsia and eclampsia. Cochrane Database Syst Rev. 2010(8):CD007388. Epub 2010/08/06.

Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994;171:818-22. Epub 1994/09/01.

Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol. 1990;76:1070-5. Epub 1990/12/01.

GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. BJOG. 2003;110:27-32. Epub 2002/12/31.

Thornton JG, Hornbuckle J, Vail A, Spiegelhalter DJ, Levene M. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. Lancet. 2004;364:513-20. Epub 2004/08/11.

van Pampus MG, Wolf H, Westenberg SM, van der Post JA, Bonsel GJ, Treffers PE. Maternal and perinatal outcome after expectant management of the hellpsyndrome compared with pre-eclampsia without hellpsyndrome. Eur J Obstet Gynecol Reprod Biol. 1998;76:31-6. Epub 1998/03/03.

Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443-51. Epub 2006/06/09.

Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf. 2003;12:633-46. Epub 2004/02/07.

Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992;80:429-32. Epub 1992/09/01.

Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet. 1997;350:1446-7. Epub 1997/11/26.

Velazquez-Armenta EY, Han JY, Choi JS, Yang KM, Nava-Ocampo AA. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy. 2007;26:51-66. Epub 2007/04/25.

Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990;162:960-6; discussion 6-7. Epub 1990/04/01.

Weitz C, Khouzami V, Maxwell K, Johnson JW. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet. 1987;25:35-40. Epub 1987/02/01.

Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301:587-9. Epub 1990/09/22.

Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984;150:831-5. Epub 1984/12/01.

El Guindy AA, Nabhan AF. A randomized trial of tight vs. less tight control of mild essential and gestational hypertension in pregnancy. J Perinat Med. 2008;36:413-8. Epub 2008/07/09.

Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, et al. The Control of Hypertension In Pregnancy Study pilot trial. BJOG. 2007;114:770, e13-20. Epub 2007/05/23.

von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87-92. Epub 2000/02/16.

Nabhan AF, Elsedawy MM. Tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension. Cochrane Database Syst Rev. 2011(7):CD006907. Epub 2011/07/08.

Paternoster DM, Stella A, Mussap M, Plebani M, Gambaro G, Grella PV. Predictive markers of preeclampsia in hypertensive disorders of pregnancy. Int J Gynaecol Obstet. 1999;66:237-43. Epub 1999/12/02.

Calvert SM, Tuffnell DJ, Haley J. Poor predictive value of platelet count, mean platelet volume and serum urate in hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996;64:179-84. Epub 1996/02/01.

Anumba DO, Lincoln K, Robson SC. Predictive value of clinical and laboratory indices at first assessment in women referred with suspected gestational hypertension. Hypertens Pregnancy. 2010;29:163-79. Epub 2010/04/07.

Cruickshank DJ, Robertson AA, Campbell DM, MacGillivray I. Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. Eur J Obstet Gynecol Reprod Biol. 1992;45:47-51. Epub 1992/06/16.

Pickles CJ, Broughton Pipkin F, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol. 1992;99:964-8. Epub 1992/12/01.

Pickles CJ, Symonds EM, Broughton Pipkin F. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol. 1989;96:38-43. Epub 1989/01/01.

Rubin PC, Butters L, Clark DM, Reynolds B, Sumner DJ, Steedman D, et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet. 1983;1:431-4. Epub 1983/02/26.

Plouin PF, Breart G, Llado J, Dalle M, Keller ME, Goujon H, et al. A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Br J Obstet Gynaecol. 1990;97:134-41. Epub 1990/02/01.

el-Qarmalawi AM, Morsy AH, al-Fadly A, Obeid A, Hashem M. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet. 1995;49:125-30. Epub 1995/05/01.

Bharathi KN, Prasad KVSRG, Jagannath P, Nalini KS. A comparison of nifedipine with methyldopa for control of blood pressure in mild to moderate pregnancy induced hypertension. Journal of Clinical and Diagnostic Research. 2010;4:2406-9.

Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG. 2007;114:300-9. Epub 2006/12/15.

Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG. 2007;114:289-99. Epub 2006/12/15.

Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev. 2010(12):CD000127. Epub 2010/12/15.

Duley L, Henderson-Smart DJ, Chou D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev. 2010(10):CD000128. Epub 2010/10/12.

Duley L, Gulmezoglu AM, Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev. 2010(9):CD002960. Epub 2010/09/09.

Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2006(3):CD001449. Epub 2006/07/21.

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327:955-60. Epub 2003/10/25.

Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, Lopez JC. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006;128:157-62. Epub 2006/04/20.

Vermillion ST, Scardo JA, Newman RB, Chauhan SP. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol. 1999;181:858-61. Epub 1999/10/16.

Hennessy A, Thornton CE, Makris A, Ogle RF, Henderson-Smart DJ, Gillin AG, et al. A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial. Aust N Z J Obstet Gynaecol. 2007;47:279-85. Epub 2007/07/14.

Manzur-Verastegui S, Mandeville PB, Gordillo-Moscoso A, Hernandez-Sierra JF, Rodriguez-Martinez M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol. 2008;35:580-5. Epub 2007/12/12.

Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2011;119:78-85. Epub 2011/10/12.

Rep A, Ganzevoort W, Van Wassenaer AG, Bonsel GJ, Wolf H, De Vries JI. One-year infant outcome in women with early-onset hypertensive disorders of pregnancy. BJOG. 2008;115:290-8. Epub 2007/11/01.

Visser W, van Pampus MG, Treffers PE, Wallenburg HC. Perinatal results of hemodynamic and conservative temporizing treatment in severe pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 1994;53:175-81. Epub 1994/03/15.

Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006(3):CD004454. Epub 2006/07/21.

Tukur J, Umar NI, Khan N, Musa D. Comparison of emergency caesarean section to misoprostol induction for the delivery of antepartum eclamptic patients: a pilot study. Niger J Med. 2007;16:364-7. Epub 2007/12/18.

Alexander JM, Bloom SL, McIntire DD, Leveno KJ. Severe preeclampsia and the very low birth weight infant: is induction of labor harmful? Obstet Gynecol. 1999;93:485-8. Epub 1999/04/24.

Nassar AH, Adra AM, Chakhtoura N, Gomez-Marin O, Beydoun S. Severe preeclampsia remote from term: labor induction or elective cesarean delivery? Am J Obstet Gynecol. 1998;179:1210-3. Epub 1998/11/20.

Matchaba PT, Moodley J. WITHDRAWN: Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database Syst Rev. 2009(3):CD002076. Epub 2009/07/10.

Fonseca JE, Mendez F, Catano C, Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol. 2005;193:1591-8. Epub 2005/11/02.

Isler CM, Magann EF, Rinehart BK, Terrone DA, Bass JD, Martin JN, Jr. Dexamethasone compared with betamethasone for glucocorticoid treatment of postpartum HELLP syndrome. Int J Gynaecol Obstet. 2003;80:291-7. Epub 2003/03/12.

Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev. 2010(9):CD008148. Epub 2010/09/09.

Pattinson RC, Norman K, Odendaal HJ. The role of Doppler velocimetry in the management of high risk pregnancies. Br J Obstet Gynaecol. 1994;101:114-20. Epub 1994/02/01.

Pattison N, McCowan L. WITHDRAWN. Cardiotocography for antepartum fetal assessment. Cochrane Database Syst Rev. 2010(1):CD001068. Epub 2010/01/22.

Lalor JG, Fawole B, Alfirevic Z, Devane D. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev. 2008(1):CD000038. Epub 2008/02/07.


comments powered by Disqus

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2015 Revista Colombiana de Obstetricia y Ginecología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN Impreso       0034-7434 

ISSN Electrónico   2463-0225

https://doi.org/10.18597/issn.0034-7434